News

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc. SRPT stock experienced a steep decline of approximately 40% in premarket trading on Monday following a sobering safety update for its Duchenne muscular dystrophy (DMD ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a ...
A second Duchenne patient being treated with Sarepta's gene therapy has died, sending the biotech's stock plummeting. Thursday, July 31, 2025 Biotech's Future - Innovation, AI and our Competitive Edge ...
Sarepta Therapeutics Stock Plummets as Second Patient Dies After Taking Its Drug . Sarepta Therapeutics shares are plunging more than 30% in premarket trading after a second Duchenne ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died. The patient was being treated for Duchenne muscular dystrophy, and ...
On June 16, 2025, shares of Sarepta stock dropped more than 47% after the company "provided a safety update regarding ELEVIDYS" and reported a second "case of acute liver failure ...
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between ...